secwatch.observer — SEC 8-K summary
======================================

Issuer:     ALNYLAM PHARMACEUTICALS, INC. (ALNY)
CIK:        0001178670
Form:       8-K
Filed at:   2023-05-04T23:59:59+00:00
Accession:  0001157523-23-000728
Event type: earnings
Sentiment:  positive
Materiality: 0.78
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Alnylam Q1 product rev $276M (+48% YoY); ALN-APP CNS data positive; FY guidance reaffirmed
--------------------------------------------------------------------------------

- Q1 net product revenue $276M (+48% YoY); AMVUTTRA $102M and ONPATTRO $102M drove TTR growth of 49%.
- GAAP net loss $174M ($1.40/share); non-GAAP net loss $132M ($1.06/share). FY23 revenue guidance $1.2B-$1.285B reaffirmed.
- Positive interim Phase 1 data for ALN-APP in early-onset Alzheimer's: first human RNAi CNS gene silencing demonstrated.
- 18-month APOLLO-B data submitted to FDA for ONPATTRO in cardiomyopathy; KARDIA-1 (zilebesiran) topline expected mid-2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1178670/000115752323000728/0001157523-23-000728-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1178670/000115752323000728/a53393280.htm
  HTML page:      https://secwatch.observer/filing/0001157523-23-000728

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer